Fingerprint
Dive into the research topics of 'Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically